Psychiatry and Neurology, Neurology · Oklahoma City, OK
NPI
1770998460
Since 2014
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
820 NE 15th St
Oklahoma City, OK, 73104
Phone (405) 271-6242
Groups this clinician bills Medicare through
Medicare paid, 2024
$895K
26,804 services
Medicare patients, 2024
199
Average age 60
Drug cost, 2024
$3.6M
2,529 prescriptions
Company payments, 2025
$50K
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Chelsea Berkley was code J2350 (injection, ocrelizumab, 1 mg), 12,300 times for 13 patients. In total Chelsea Berkley billed 26,804 services in 19 codes, and Medicare paid $895K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-09-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2350 Injection, ocrelizumab, 1 mg | Office | 12,300 | 13 | $44.41 | $546K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 970 | 25 | $0.22 | $215 |
| 99214 Office E&M - Established | Office | 171 | 163 | $73.79 | $13K |
| 96413 Chemotherapy Administration | Office | 100 | 34 | $86.10 | $8,610 |
| 96415 Chemotherapy Administration | Office | 61 | 28 | $19.51 | $1,190 |
| 96375 Injection Administration | Office | 57 | 29 | $10.41 | $594 |
| 99205 Office E&M - New | Office | 26 | 26 | $109.73 | $2,853 |
By year: 2022 $841K for 26,603 services; 2023 $652K for 21,608 services; 2024 $895K for 26,804 services.
Medicare prescription drug claims, 2024
In 2024, the drug Chelsea Berkley prescribed most often to Medicare patients was Baclofen, with 246 prescriptions and refills. In total Chelsea Berkley wrote 2,529 Medicare prescriptions that cost $3.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Baclofen Generic | 246 | 388 | 71 | $5,017 |
| Gabapentin Generic | 193 | 331 | 45 | $3,286 |
| Dalfampridine Er Dalfampridine | 133 | 203 | 21 | $35K |
| Pregabalin Generic | 132 | 211 | 27 | $3,295 |
| Teriflunomide Generic | 122 | 128 | 20 | $70K |
| Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine | 115 | 115 | 23 | $5,197 |
| Modafinil Generic | 111 | 157 | 32 | $17K |
| Tizanidine Hcl Generic | 99 | 225 | 33 | $2,107 |
| Kesimpta Pen Ofatumumab | 78 | 84 | 12 | $776K |
| Duloxetine Hcl Generic | 58 | 126 | 19 | $2,134 |
| Clonazepam Generic | 53 | 53 | 14 | $187 |
| Carbamazepine Er Carbamazepine | 46 | 54 | Under 11 | $3,241 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 41 | 78 | 14 | $266 |
| Aubagio Teriflunomide | 35 | 43 | Under 11 | $387K |
| Glatiramer Acetate Generic | 34 | 34 | Under 11 | $60K |
Brand drugs: 416 claims; generic drugs: 2,113 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Chelsea Berkley $50K ($50K in general payments such as food, travel and fees) from 17 companies. The largest payer was EMD Serono, Inc. with $32K.
| Company | Payments | Amount |
|---|---|---|
| EMD Serono, Inc. MRK.DE | 50 | $32K |
| TG Therapeutics, Inc. TGTX | 41 | $16K |
| Novartis Pharmaceuticals Corporation NVS | 21 | $581 |
| Genzyme Corporation SNY | 5 | $424 |
| Biogen, Inc. BIIB | 11 | $330 |
| Amgen Inc. AMGN | 12 | $263 |
| Genentech USA, Inc. ROG.SW | 6 | $245 |
| Abbvie Inc. ABBV | 9 | $185 |
| ANI Pharmaceuticals, Inc. ANIP | 4 | $112 |
| Pfizer Inc. PFE | 5 | $82.93 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.